ArticlemBio2020
The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant Klebsiella pneumoniae.
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- The immune protection of OMP16-specific IgM against Brucella infection.BMC biology · 2026Article
- Tau pSer396 and pSer404 Define Distinct Epitope Regions Linked to Different Antibody Functions.bioRxiv : the preprint server for biology · 2026Article
- Article
- Co-Occurrence of Resistance to Aminoglycosides and Carbapenems inInternational journal of microbiology · 2026Review
- Article
- Conserved molecular chaperone PrsA stimulates protective immunity against group A Streptococcus.NPJ vaccines · 2024Article
- Tau-targeting therapies for Alzheimer disease: current status and future directions.Nature reviews. Neurology · 2023Review
- Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations.Advances in respiratory medicine · 2022Article
- Patient-Derived Antibody Data Yields Development of Broadly Cross-Protective Monoclonal Antibody against ST258 Carbapenem-ResistantMicrobiology spectrum · 2022Article
- LPS O Antigen Plays a Key Role in Klebsiella pneumoniae Capsule Retention.Microbiology spectrum · 2022Article
- A Mosquito AgTRIO Monoclonal Antibody Reduces EarlyInfection and immunity · 2022Article
- Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies.Journal of innate immunity · 2022Review
- Host defense against the infection ofFrontiers in cellular and infection microbiology · 2022Review
- Serum Antibody Responses against Carbapenem-Resistant Klebsiella pneumoniae in Infected Patients.mSphere · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Monoclonal antibodies (MAbs) have the potential to assist in the battle against multidrug-resistant bacteria such as carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.